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Cyclic pentapeptide Tyr-c[D-Lys-Phe-Phe-Asp]NH2, based on the structure of endomorphin-2 (EM-2),
which shows high affinity to the m-opioid receptor (MOR) and a very strong antinociceptive activity in
mice was used as a parent compound for the structureeactivity relationship studies. In this report we
synthesized analogs of a general sequence Dmt-c[D-Lys-Xaa-Yaa-Asp]NH2, with D-1- or D-2-naphthyl-3-
alanine (D-1-Nal or D-2-Nal) in positions 3 or 4.
In our earlier papers we have indicated that replacing a phenylalanine residue by the more extended
aromatic system of naphthylalanines may result in increased bioactivities of linear analogs. The data
obtained here showed that only cyclopeptides modified in position 4 retained the sub-nanomolar MOR
and nanomolar k-opioid receptor (KOR) affinity, similar but not better than that of a parent cyclopeptide.
In the in vivo mouse hot-plate test, the most potent analog, Dmt-c[D-Lys-Phe-D-1-Nal-Asp]NH2,
exhibited higher than EM-2 but slightly lower than the cyclic parent peptide antinociceptive activity after
peripheral (ip) and also central administration (icv). Conformational analyses in a biomimetic environ-
ment and molecular docking studies disclosed the structural determinants responsible for the different
pharmacological profiles of position 3- versus position 4-modified analogs.
© 2015 Published by Elsevier Masson SAS.1. Introduction
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interest for chemists and pharmacologists. Since the endogenous
opioid system is known to play a crucial role in pain processing,
many endogenous opioid peptides and their synthetic analogs have
been studied extensively in order to develop new candidate drugs
with antinociceptive activity [1]. There are at least three major
types of opioid receptors, m, d and k (or MOR, DOR and KOR,
respectively), with distinct profiles clearly distinguishing each one
from the others. The scientific breakthrough in opioid receptor
research came with obtaining their crystal structures [2e4]. There
is evidence that in their inactive form, receptors share a conserved
wide-open binding pocket and may function as oligomers [3,5].
According to Yamazaki et al. [6], physiological activity of opioid
peptides is determined by the conformation of the N-terminal
portion, the so called “message” sequence. The remaining C-ter-
minal fragment represents the “address”. This portion is supposed
to stabilize the bioactive conformation, among various
R. Perlikowska et al. / European Journal of Medicinal Chemistry 109 (2016) 276e286 277conformations accessible to the N-terminal message sequence [7].
As it was well established, Tyr1 and Phe3/Phe4 residues commonly
found in the group of endogenous opioid ligands and their syn-
thetic analogs are structural determinants for binding to opioid
receptors [6,8]. Their reciprocal distances and disposition deeply
influence the affinity and selectivity for the different opioid re-
ceptor subtypes [9,10].
A fundamental step toward the rational design of potent and
safe therapeutics is understanding their interactions with receptors
which are involved in mediation and modulation of different
pharmacological effects. To improve receptor recognition, reduce
the molecular conformational freedom, stabilize the peptide in
biological fluids and increase membrane permeation, the cycliza-
tion of linear sequences was frequently adopted in peptide chem-
istry [11e14]. The structure of cyclic peptides could be considered a
suitable scaffold for arrangement of the pharmacophoric groups in
a restricted regions of the space surrounding the molecule [9].
In the search for new, potent antinociceptive agents, we have
been synthesizing cyclic analogs based on the structure of
endomorphin-2, Tyr-Pro-Phe-PheNH2 (EM-2), with conserved free
amino group at the N-terminus which is thought to be crucial for
the binding to the MOR [15]. These analogs were cyclized through
an amide bond between the side-chains of bifunctional amino acids
incorporated into the structure of EM-2 [16e19]. Our first very
potent cyclic analog was a pentapeptide Tyr-c[D-Lys-Phe-Phe-Asp]
NH2 (analog 1), which displayed a similar to EM-2 MOR affinity,
greatly improved stability in the rat brain homogenate and much
stronger and longer lasting antinociceptive activity after intra-
cerebroventricular (icv) administration [16]. This analog elicited
analgesia also after peripheral injection and this effect was reversed
by the concomitant icv administration of the MOR antagonist, b-
funaltrexamine (b-FNA), which indicated that antinociception was
mediated by the MOR receptors in the brain. Enzymatic stability
and the ability to cross the bloodebrain barrier (BBB) are two most
desirable features of new analgesic drug candidates which made
this cyclic peptide of considerable interest. Therefore, we designed
further modifications of this pentapeptide, in order to elucidate
structureeactivity relationships [17e21]. Continuing these studies,
here we report on a new series of cyclic analogs obtained by the
introduction of D-1-naphthyl-3-alanine (D-1-Nal) or D-2-
naphthyl-3-alanine (D-2-Nal) instead of the Phe residues in posi-
tions 3 or 4 of our parent analog 1. The introduction of a D-amino
acid residue into one of these positions in the macrocycle is ex-
pected to strongly impact the accessible backbone conformations,
since a heterochiral residue tends to stabilize alternative secondary
structures. Besides, Nal contains a more extended aromatic ring
system and therefore introduces an additional steric hindrance.
Additionally, Tyr residue in position 1 was replaced by 20,60-dime-
thyltyrosine (Dmt), known to remarkably enhance opioid receptor
binding affinities [22,23]. Introduction of the more lipophilic amino
acid residues was aimed at increasing the BBB permeability, while
retaining or enhancing the biological activity. The biological prop-
erties of the new cyclopeptides were evaluated in the radioligand
receptor binding experiments in the rat or guinea pig brain mem-
brane homogenates, followed by determination of their agonist
potencies in a calcium mobilization assay performed on cells
expressing opioid receptors and chimeric G proteins. The anti-
nociceptive activity of the most promising compound was studied
in vivo in the mouse hot-plate test. The 3D structure analyses of all
new cyclopeptides in solution were performed, and their bioactive
conformations when docked into a model of the MOR were ob-
tained. In each test the results were compared to the parent
cyclopeptide 1.2. Results and discussion
2.1. Synthesis
Peptides were assembled and cyclized on a solid support using a
Fmoc/t-Bu-based strategy with the hyper-acid labile 4-methyltrityl
(Mtt) and 2-phenyl-isopropyl ester (O-2 PhiPr) groups [24,25] for
the selective amine/carboxyl side-chain protection of D-Lys and
Asp, respectively. Analytical properties of the analogs are summa-
rized in Table 1. High resolution mass spectrometry (HR-MS) ex-
periments confirmed the mass identity of all synthesized peptides.
RP-HPLC analyses of the final purified products indicated purity of
97% or greater. The structures of the peptides were analyzed by 1H
NMR and 2D gCOSY experiments which allowed for the unambig-
uous assignment of all protons (see Experimental Section).
2.2. Enzymatic stability
The stability of the new cyclopeptides toward enzymatic
degradation were verified by measuring their hydrolysis rates in
the presence of the rat brain homogenate (Table 1). After 90 min
incubation, all cyclopeptides (including parent compound 1)
remained intact in 85e95%, while EM-2 was almost completely
digested. The obtained data confirmed that cyclization protects
peptides against proteolytic digestion and confers stability in the
biological fluids [26]. The cyclic analogs resistant to enzymatic
hydrolyses usually exhibit improved bioactivities and bio-
availabilities, in comparison with their linear counterparts.
2.3. Receptor binding and functional activity
Opioid receptor binding affinities of new compounds 2e5 for
the MOR, DOR and KOR were determined by radioligand compe-
tition analysis using [3H]DAMGO, [3H][Ile5,6]deltorphin-2 and [3H]
nor-BNI, respectively. The IC50 values were determined from loga-
rithmic doseedisplacement curves, and the values of the inhibitory
constant (Ki) of peptides were calculated according to the equation
of Cheng and Prusoff [27].
The Ki values are summarized in Table 2. Analogs 2 and 3with D-
1-Nal or D-2-Nal in position 3, respectively, showed weak affinity
for theMOR, did not bind to the DOR and hadweak or no affinity for
the KOR. Analogs 4 and 5, similarlymodified at position 4, displayed
sub-nanomolar MOR affinities compared with the parent com-
pounds, EM-2 and analog 1. They exhibited also nanomolar KOR
affinities, showing weak binding to the DOR (not detectable in case
of EM-2).
The pharmacological profiles of analogs 1e5were characterized
in calcium mobilization functional assay [19,28,29]. The concen-
trationeresponse curves of all tested compounds are shown in
Fig. 1AeC and the calculated agonist potencies (pEC50) and effi-
cacies (a) of the analogs are summarized in Table 3. EM-2, DPDPE,
and dynorphin A (Dyn A) were used as the reference full agonists
for calculating intrinsic activity at the MOR, DOR and KOR,
respectively. In the CHOMOR cells, stably expressing the Gaqi5
chimeric protein, compounds 2 and 3 displayed similar potency as
the referenceMOR agonist (7.70 and 7.94, respectively, compared to
7.88 for EM-2), associated with a significant reduction in efficacy
(0.42 ± 0.06 and 0.49 ± 0.03) (Fig. 1A). Cyclopeptides 1, 4 and 5
mimicked the stimulatory effect of EM-2 (Fig. 1A), displaying a
slight reduction of efficacy (0.83 ± 0.09, 0.83 ± 0.05 and 0.75 ± 0.06,
respectively) but high potency (8.69, 8.25 and 8.44, respectively).
In the CHODOR cells, stably expressing the GaqG66Di5 chimeric
protein (Fig. 1B), analogs 2 and 3 were completely inactive, while 4
and 5 behaved as partial agonists (0.50 ± 0.05 and 0.31 ± 0.06,
respectively) showing potencies (7.19 and 7.27, respectively) not far
Table 1
Physicochemical data and enzymatic stability of the cyclic pentapeptide analogs.
Compd Sequence Formula m/z[M þ H]þa RP-HPLC Rt (min)b Area [%]c
Calcd Obsd
Tyr-Pro-Phe-Phe-NH2d (EM-2) C32H37N5O5 571.70 571.85 17.25 0.61 ± 0.04
1 Tyr-c[D-Lys-Phe-Phe-Asp]NH2d C37H45N7O7 700.345 700.345 20.50 95.97 ± 0.70***
2 Dmt-c[D-Lys-D-1-Nal-Phe-Asp]NH2 C43H51N7O7 778.392 778.387 16.21 93.80 ± 0.50***
3 Dmt-c[D-Lys-D-2-Nal-Phe-Asp]NH2 C43H51N7O7 778.392 778.387 16.38 85.42 ± 1.00***
4 Dmt-c[D-Lys-Phe-D-1-Nal-Asp]NH2 C43H51N7O7 778.392 778.385 16.02 95.98 ± 2.02***
5 Dmt-c[D-Lys-Phe-D-2-Nal-Asp]NH2 C43H51N7O7 778.392 778.388 16.10 95.62 ± 0.81***
***p < 0.001 as compared to EM-2 by using one-way ANOVA followed by the StudenteNewmaneKeuls test.
a Observed by ESI-MSþ ionization.
b Rt with Vydac C18 column (5 mm, 4.6  250 mm) using the solvent system 0.1% TFA in water (A) and 80% acetonitrile in water containing 0.1% TFA (B) and a linear gradient
of 0e100% solvent B in 25 min, flow rate 1 mL/min.
c Amount of peptide remained after 90 min incubation with rat brain homogenate.
d Data from Ref. [16].
Table 2
Opioid receptor binding of the cyclic pentapeptide analogs.
Compd Kia[nM]
MOR DOR KOR
EM-2 0.49 ± 0.02 9614.70 ± 834.50 7827.67 ± 948.20
1 0.35 ± 0.02 170.86 ± 3.5 1.12 ± 0.20
2 69.18 ± 1.20 9173.80 ± 920.60 56.62 ± 2.50
3 16.82 ± 0.60 4248.85 ± 566.50 750.70 ± 4.10
4 0.25 ± 0.02 51.20 ± 3.00 1.78 ± 0.15
5 0.44 ± 0.03 110.35 ± 8.10 1.02 ± 0.40
a Binding affinities are given as Ki values determined by competitive displace-
ment of the selective radioligands, [3H]DAMGO or [3H][Ile5,6]deltorphin-2 using rat
brain membranes, and [3H]nor-BNI using guinea pig brain membranes. All values
are expressed as mean ± SEM of three independent experiments performed in
duplicate.
Fig. 1. Concentration response curves for the cyclic pentapeptide analogs 1e5 and EM-2 (A), DPDPE (B) and Dyn A (C) in calcium mobilization experiments performed in A) CHOMOR,
B) CHODOR and C) CHOKOR cells, respectively.
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incomplete.
Finally, in the CHOKOR cells stably expressing the Gaqi5 chimeric
protein, compound 1 mimicked the stimulatory effect of Dyn A,
showing high potency (8.18) and maximal effect (106 ± 9%). Com-
pound 4 exhibited also relatively high potency (7.38), associated
however with a significant reduction of maximal effect (79 ± 6%).
Peptides 2, 3 and 5 exhibited lower potency (5.77e6.99) and effi-
cacy (Fig. 1C).
Summing up, the parent peptide 1 was a mixed MOR/KOR full
agonist, with similar potency at both these receptors. Analogs 4 and
5 also behaved as mixed MOR/KOR agonists but showed signifi-
cantly higher potency and efficacy at the MOR, being therefore
more selective than 1. Compounds 2 and 3 were partial MOR ago-
nists with moderate selectivity for this receptor.2.4. Antinociceptive activity
The antinociceptive effect of analogs was assessed in the mouse
hot-plate test which evaluates central pain attenuation after
applying an acute thermal stimuli and was compared to the effect
produced by EM-2. Groups of mice were injected icv and the hot-
plate responses were measured 10 min after injection. The results
obtained after the icv administration of peptides showed that an-
alogs 2 and 3 (ED50 for jumping 0.714 and 0.533 mg/animal,
respectively) produced responses slightly better than EM-2 (ED50
for jumping 1.820 mg/animal) despite their lower MOR affinity,
what could be explained by much higher enzymatic stability of the
cyclopeptides. The strongest antinociceptive effect, similar to that
of the parent peptide 1, was produced by 4 and 5 (ED50 for jumping0.05, 0.06 and 0.08 mg/animal, respectively) (Fig. 2) which was well
correlated with their sub-nanomolar MOR and nanomolar KOR
affinity.
The results of the hot-plate test after ip administration of pep-
tides are shown in Fig. 3. Groups of mice were injected the cyclo-
peptides ip in a dose range of 0.1e10 mg/kg (except analogs 2 and 3
which were injected only in two higher doses) and the hot-plate
responses were measured 15 min after injection. Analogs 1, 4 and
5 (ED50 for jumping <0.01, 1.160 and 3.244 mg/kg, respectively)
showed significant, dose-dependent antinociceptive activity (88,
82 and 55% at 10 mg/kg, respectively), while for 2 and 3 much
weaker effects were observed only at the highest dose (17 and 24%,
respectively).
The time-course experiments were performed following the ip
administration of two best analogs 4 and 5 at a dose of 3 mg/kg and
compared with 1 (Fig. 4). The hot-plate responses were measured
Table 3
Effects of novel cyclic pentapeptide analogs at human recombinant opioid receptors coupled with calcium signaling via chimeric G proteins.
Compd MOR DOR KOR
pEC50a (CL95%) a ± SEMb pEC50 (CL95%) a ± SEM pEC50 (CL95%) a ± SEM
DPDPE Inactivec 7.57 (7.41e7.73) 1.00 Inactivec
Dyn A 6.67d (6.17e7.17) 0.83 ± 0.10d 7.73 (7.46e8.00) 0.99 ± 0.04d 8.35 (8.16e8.53) 1.00
EM-2 7.88 (7.72e8.05) 1.00 Inactivec Inactivec
1 8.69 (8.10e9.29) 0.83 ± 0.09 Crc incomplete 8.18 (8.01e8.36) 1.00 ± 0.01
2 7.70 (7.46e7.94) 0.42 ± 0.06* Inactivec 5.89 (5.62e6.17) 0.43 ± 0.05*
3 7.94 (7.64e8.24) 0.49 ± 0.03* Inactivec 5.77 (5.44e6.09) 0.31 ± 0.04*
4 8.25 (8.08e8.43) 0.83 ± 0.05 7.19 (6.89e7.49) 0.50 ± 0.05* 7.38 (7.24e7.52) 0.74 ± 0.06*
5 8.44 (8.20e8.69) 0.75 ± 0.06* 7.27 (6.87e7.68) 0.31 ± 0.06* 6.99 (6.71e7.27) 0.44 ± 0.04*
EM-2, DPDPE and Dyn A were used as reference agonists for calculating intrinsic activity at the MOR, DOR, and KOR, respectively.
*p < 0.05 according to one way ANOVA followed by the Dunnett test for multiple comparisons.
a Agonist potency values (pEC50) and.
b Efficacy values (a).
c Inactive means that the compound was inactive as agonist up to 1 mM.
d Data from Ref. [28]. The data represent mean ± SEM of at least 3 separate experiments performed in duplicate.
Fig. 2. The effect of different doses of the cyclic pentapeptide analogs 1e5 and EM-2 in
the mouse hot-plate test. Results are expressed as percentage (mean ± SEM) of the
maximal possible effect (%MPE) for the inhibition of jumping induced by icv injection
of a peptide. Number of animals per group ranged between 7 and 10.
Fig. 3. The effect of different doses of the cyclic pentapeptide analogs 1e5 in the
mouse hot-plate test. Results are expressed as percentage (mean ± SEM) of the %MPE
for the inhibition of jumping induced by ip injection of a peptide. Number of animals
per group ranged between 7 and 10.
Fig. 4. Antinociceptive effect of 1, 4 and 5 (3 mg/kg) in the mouse hot-plate test at
different times after ip injection. Results are expressed as percentage (mean ± SEM) of
the %MPE for the inhibition of jumping. Number of animals per group ranged between
7 and 10.
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effects were observed 15 min after injection, then slowly declined.
Two of the new lactams (4 and 5) showed, similarly to parent
compound 1, efficacy to both, MOR and KOR. Compounds which
display strong antinociception after peripheral administration and
bind simultaneously to MOR and KOR may represent a newgeneration of pain relieving peptides with reduced abuse liability.
Central action of KOR agonists produces analgesia accompanied by
some dysphoric effects [30,31], and that property has limited the
therapeutic development of this class of ligands [32,33]. However,
some evidence suggests that mixed MOR/KOR agonists display
fewer side-effects. Indeed, MOR/KOR agonists of alkaloid structure,
such as ethylketazocine (EKC), have been known and used to treat
cocaine addiction [31,34]. Presumably, the presence of MOR agonist
activity can neutralize any dysphoria induced by KOR agonism
[31,35].
2.5. Conformational analysis
The different activity profiles of the cyclopeptides prompted us
to investigate the preferred conformations of the new analogs 2e5
in solution by 1H NMR spectroscopy and restrained molecular dy-
namics (MD), as previously reported [36]. NMR spectra were
recorded in 8:2 mixtures of deuterated dimethyl sulfoxide (DMSO-
d6) and H2O. Such mixed solvent system have been recommended
by several authors as an excellent representative of biological fluids
[37,38]. All the spectra showed a single set of resonances, sugges-
tive of conformational homogeneity or a rapid equilibrium between
conformers. It is apparent that peptides 2 and 3, containing D-Nal at
position 3, had very similar spectra, with the diverse resonances at
nearly the same chemical shift values. In a similar way, peptides 4
R. Perlikowska et al. / European Journal of Medicinal Chemistry 109 (2016) 276e286280and 5 containing D-Nal at position 4, displayed very similar 1H NMR
spectra (see Experimental Section, NMR analysis section).
Variable-temperature (VT) 1H NMR experiments performed in
8:2 mixture of DMSO-d6/H2O were used to detect if amide protons
were involved in the intramolecular hydrogen bonding or were
solvent exposed (Table 4). Cyclopeptides 2 and 3 showed compar-
atively lower Dd/DT values for Asp5NH in respect to other amide
protons (Dd/DT in p.p.b./K, for 2 ¼ 2.4, for 3 ¼ 2.6), suggestive of
some preference for conformations having hydrogen bonded
AspNH (jDd/DTj  2.5 p.p.b./K) [39]. On the other hand, the cyclo-
peptides 4 and 5 showed a low Dd/DT value for D-Phe3NH (Dd/
DT ¼ 1.6 p.p.b./K) but the Dd/DT values for the remaining amide
protons of the macrocycle were only slightly higher, ranging
from 2.5 to 3.6 p.p.b./K, thus suggesting that these peptide might
adopt a variety of conformations characterized by weak hydrogen
bonds.
Detailed conformational analyses of cyclopeptides 2e5 were
performed by 2D NMR spectroscopy and MD simulations. The
compounds were analyzed by 2D-ROESY in the biomimetic DMSO-
d6/H2O (8:2) mixed solvent. Cross-peak intensities were ranked to
inter plausible inter-proton distances as restraints (Supplementary
Material). Structures consistent with ROESY were obtained by
simulated annealing with restrained MD in a box of explicit TIP3P
equilibrated water molecules. The u bonds were set at 180; as it is
well established that peptides comprising only secondary amide
bonds adopt all-trans conformations. In any case, the absence of
Ha(i)Ha(i þ 1) cross-peaks reasonably excluded the occurrence of
cis peptide bonds. The structures were minimized with the AMBER
force field [40] and clustered by the rmsd analysis of backbone
atoms.
For analog 2, the procedure gave one major cluster comprising
the large majority of the structures. The representative structure
with the lowest energy was selected and analyzed (Fig. 5). In the
ROESY-derived structure, the Dmt residue was situated above the
plane of the macrocycle (Fig. 5). The backbone adopted an inverse
type II b-turn secondary structure centered on D-1-Nal-Phe, sta-
bilized by a hydrogen bond between D-Lys carbonyl oxygen and
AspNH, in agreement with the VT-NMR experiments (Table 4). On
the other hand, 2 showed also a hydrogen bond between D-LysNH
and AspC ¼ O, not predicted by VT-NMR analysis; possibly this
hydrogen bond was not as stable as the previous one, due to the
floppy geometry of the long Lys side chain connecting Asp.
On repeating the procedure described above, analog 3 gave a
single major cluster of conformers, whose representative, lower
energy model was characterized by a type I b-turn secondary
structure centered on D-2-Nal-Phe, with a hydrogen bond between
D-Lys carbonyl oxygen and AspNH (Fig. 5). Possibly, the presence of
the 2-Nal substituent instead of the 1-Nal isomer at position 3 of
the macrocycle forced the phenyl side chain of Phe4 above the
molecular plane, so adopting a pseudo axial disposition, impacting
also the geometry of the flexible Lys (CH2)4 chain.
The analysis of analog 4 gave onemajor cluster showing the Dmt
residue in a pseudo equatorial position in respect to themacrocycle,
and a second minor cluster in which Dmt was located above the
plane of the macrocycle. The respective structures 4A and 4B, withTable 4
Dd/DT values (p.p.b./K) for the amide protons of the cyclic pentapeptide analogs 2e5
in 8:2 DMSO-d6/H2O.
Compd D-Lys2NH Xaa3NH Yaa4NH Asp5NH D-LysNHε CONH2
2 4.3 3.3 8.2 2.4 3.6 5.7/6.2
3 4.6 4.1 6.1 2.6 3.9 4.5/4.5
4 2.5 1.6 3.6 2.5 3.5? 4.5/4.7
5 2.5 1.6 3.2 2.9 3.1 4.7/4.7the lowest energies (4A comparatively more stable than 4B) were
selected and analyzed (Fig. 5). Both conformations were charac-
terized by a type II b-turn centered on Phe-D-1-Nal with a hydrogen
bond between D-LysNH and AspC ¼ O. Nevertheless, the VT-NMR
analysis indicated that other hydrogen bonded structures
involving either D-LysNH and/or PheNH were possible (Table 4).
Reasonably, 4A and 4B represented conformers in equilibrium,
whose average accounted for the medium ROESY cross-peak be-
tween PheNH and D-LysHa (corresponding to a distance of about
3 Å). These correlations and the secondary structures of 2, 3, 4A, 4B,
and 5 along with the explicit hydrogen bonds, are also sketched in
Fig. 8 (Discussion Section).
Finally, the investigation of the conformational features of
analog 5 by 2D ROESYand MD gave, after clustering, a single model
structure very similar to 4A (Fig. 5). Accordingly, 5 showed a clear
hydrogen bonded type II b-turn centered on Phe-D-2-Nal. Unlike in
case of 2 and 3, the substitution of 1-Nal with 2-Nal did not prevent
5 from adopting the same backbone geometry as 4A, indicating that
also the stereochemistry array of the residues (LDDLL for 2 and 3,
LDLDL for 4 and 5) exerted a significant role in determining the
overall 3D structure [41,42].
The structures of 2e5 determined in solution (Fig. 5) were
compared to the in-solution conformations of the parent peptide 1
described earlier [20]. The analysis of the conformations of back-
bones and side-chains revealed that the Tyr-D-Lys-Phe portions of
4A and 5 maintained a good superimposition with the corre-
sponding portions of analog 1 sol. However, 4A and 5 differ in the
positioning of the naphthyl groups and in the conformation of Asp,
correlated to the reversal of configuration of the fourth residue. On
the other hand, the structures of 2 and 3 carrying the D-configured
residue at position 3 clearly differ from the structure of analog 1 sol.
both in terms of backbones and all side-chain orientations.
2.6. Molecular docking
All compounds were analyzed by molecular docking (MolDock)
simulations with Autodock 4.0 [43], using as initial geometries of
the ligands the ROESY-derived structures shown in Fig. 5, and the
previously reported model of human MOR (hMOR) obtained by
homology modeling [41,44,45], subsequently validated using the
crystallographic structure obtained in 2012 [2]. The results from
this procedure were followed by relaxation and optimization of the
resulting system (induced-fit). A combined quantum mechanical/
molecular mechanics (QM/MM) approach was utilized to study the
ligand-receptor complex [41,45]. In this method, an accurate but
computationally intensive QM description was used only for re-
gions where electronic interactions were occurring. The rest of the
system, whose chemical identity remained essentially the same,
was treated at the approximate classical MM level. Structures were
clustered together and representative model of each cluster was
selected based on the most favourable free energy of binding.
The compounds 4 and 5 differed only by the side-chain of the
residue present at position 4, D-1-Nal or D-2-Nal, respectively.
Regardless of this difference, both compounds were able to interact
effectively with the binding site, providing two complexes perfectly
inserted into the cavity and showing the well-known ionic inter-
action between the quaternary cationic nitrogen of Dmt and the
Asp147 (TMH III). This interaction was enhanced by a second
hydrogen bond with the Tyr326 (EL IV) (Fig. 6A and B for 4 and 5,
respectively). The AspCONH2 group of both ligands was situated in
a zone adjacent to EL II and TMH V. In this position it was able to
effectively interact with the residue Glu229 (TMH V). The aliphatic
and aromatic portions of the ligands were positioned in close
proximity to the hydrophobic pockets belonging to domains TMH I,
TMH II, TMH III and TMH VII, with the naphthalene group able to
Fig. 5. Representative lowest energy structures of 2e5, calculated by ROESY-restrained MD in a 30  30  30 Å box of standard TIP3P water molecules. Only amide and a-protons
are shown.
Fig. 6. The schematic 3D diagrams of the interactions between analog 4 (A) and analog 5 (B) with hMOR, and amino acid composition of the binding site. Residues belonging to the
hMOR are shown in wire frame, while the ligands are in sticks. Hydrogen bonds are represented by dashed lines.
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action pattern was completed by two hydrogen bonds with Lys303
(TMH VI) and Leu219 (EL III). The structural similarities described
above were confirmed by the very similar values of the free en-
ergies of binding, with 4 being only 0.9 kcal/mol more stable than 5.
The schematic 3D diagrams of the interactions between the ligands
and hMOR are shown in Fig. 6A and B, along with the amino acid
composition of the binding site.
The MolDock computations of analogs 2 and 3 confirmed also
for these compounds the occurrence of the ionic interaction with
Asp147 (TMH III), while the carbonyl group of Dmt residue inter-
acted with Tyr148 (TMH III). Compound 3 (Fig. 7B) showed two
additional hydrogen bonds with Glu229 (TMH V) and Ile296 (TMH
VI) which were not found in compound 2 (Fig. 7A). Bothcompounds displayed a piepi interaction between the naphthyl
group of Nal3 and Tyr128 (TMH II). However, in this position, the
naphthyl group was affected by a strong steric hindrance, resulting
in less stable complexes compared to 4 and 5. A measure of this
instability was given by the difference in the calculated binding free
energy of 2 and 3 compared to the value obtained for 4, amounting
to 12.7 and 10.3 kcal/mol, respectively. The schematic 3D diagrams
of the ligand-receptor interactions and the amino acid composition
of the binding site, are shown in Fig. 7.
Compared to the bioactive conformation of the parent com-
pound 1, 4 and 5 adopt within the receptor the same geometry of
Tyr-D-Lys-Phe, while the portions D-Nal-Asp are significantly
different. The reversal of stereochemistry of D-Nal4 with respect to
L-Phe4 of the parent peptide 1 drives the large naphthyl side-chain
Fig. 7. The schematic 3D diagrams of the interactions between analog 2 (A) and analog 3 (B) with hMOR, and residue composition of the binding site. Residues belonging to the
hMOR receptor are shown in wire frame, while the ligands are in sticks. Hydrogen bonds are represented by dashed lines.
Fig. 8. Sketches of the structures of 2e5 (to be compared to Fig. 5).
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tures reported in Fig. 6 show that the naphthyl group of 4 and 5 can
be easily hosted in an upper hydrophobic cavity delimited by the
residues Glu229, Lys209, Leu219, so the compounds can still effi-
ciently fit the receptor. Interestingly, the substitution of L-Phe4 by
D-Nal4 also induces a rotation of the analogs 4 and 5 within the
receptor cavity with respect to the parent analog 1. Indeed, while
the latter interacts with Tyr148 of the protein by a hydrogen-bond
with Tyr1(C]O), in 4 and 5 the phenyl of Phe3 is situated side-
by-side with Tyr148 (Fig. 6).
As for the derivatives 2 and 3, the comparison of the bioactive
structures with that of the parent analog 1 shows a completely
different binding poses (Fig. 7). Possibly, the very large side-chains
of D-Nal3 cannot easily accommodate into the small pocketdelimited by residues Asp147, Tyr148, Trp133, so the entire struc-
ture is forced to enter in a lying down position, to minimize unfa-
vorable claches.
In summary, the biological activities of the peptides 2e5 can be
correlatedwith the different structural features. The very similar 1H
NMR spectra and VT-NMR experiments for 2 and 3 and also for 4
and 5 indicate that cyclopeptide backbone conformations were
scarcely influenced by the different structures of the side-chains (1-
Nal versus 2-Nal). As a matter of fact, the 2D ROESY-derived struc-
tures of 2 and 3 showed a somewhat different display of the aryl
side-chains of D-Nal3 and Phe4, and minor differences relative to
the highly flexible (CH2)4 connector between Lys and Asp. For
compound 4, the conformational analysis gave two possible con-
formers, characterized by a rather different position of the
R. Perlikowska et al. / European Journal of Medicinal Chemistry 109 (2016) 276e286 283fundamental residue Dmt1. On the other hand, the predominant
conformer 4Awas very similar to the conformation of compound 5.
The comparison of all structures (Fig. 8) revealed that the Dmt1
residue adopted in all cases the same position, nearly equatorial to
the macrocycle. Therefore, the most striking difference between 2/
3 and 4/5 seems to be a different display of the side-chains of the
residues at the positions 3 and 4, mostly correlated to the different
stereochemistry array, LDDLL for 2 and 3, versus LDLDL for 4 and 5.
This major difference resulted in a different ability to fit the
opioid receptor. TheMolDock analyses showed the binding poses of
the cyclopeptides and the residues involved in the ligand-receptor
recognition. The computations revealed that the most relevant
differences between 2/3 and 4/5 involved the naphthyl groups.
Compared to the binding poses of 4/5, the shift of the naphthyl
groups from position 4 to position 3 had the effect of preventing the
cationepi interaction between the naphthyl group and Lys209 (EL
III), fostering instead a piepi interaction with Tyr128 (TMH II).
However, in this position, the naphthyl group of 2/3 (Fig. 7) was
affected by a strong steric hindrance, resulting in less stable com-
plexes as compared to 4/5. Interestingly, it turned out that bioactive
conformations of 2e5 are slightly different from that of the parent
analog 1. In particular, the inspection of Fig. 6 showed that, unlike 1,
these cyclopeptides reproduce most of the fundamental in-
teractions of the prototypic potent MOR-selective agonist JOM-6
(Fig. 9) [44,46].
3. Conclusion
Performing the structureeactivity relationship studies of our
cyclic pentapeptide Tyr-c[D-Lys-Phe-Phe-Asp]NH2 (1), which
showed a very strong antinociceptive activity in mice after central
and peripheral administration we obtained a series of lactams,
incorporating D-1- or D-2-Nal residues in positions 3 or 4. Analogs
modified in position 4 showed significantly higher opioid receptor
affinities and pharmacological activities than the position-3
substituted counterparts. On the other hand, substitution of D-1-
Nal versus D-2-Nal in each of the two positions produced similar
results. Pharmacological assays revealed that peptides 2 and 3,
having D-Nal in position 3, behaved as weak MOR and KORFig. 9. A sketch of the MOR-binding pose of JOM-6 (in ball and cylinders), and relevant
interactions with receptor residues (in sticks) (to be compared to Fig. 6).agonists. Peptides 4 and 5 with D-configured 1-Nal or 2-Nal in
position 4, were similarly to the parent compound 1, excellent li-
gands of MOR with sub-nanomolar affinity and good KOR ligands
with nanomolar affinity. In the calciummobilization functional test,
these two peptides were found to behave as universal opioid re-
ceptor agonists, with markedly higher potency and efficacy for the
MOR. In agreement with high MOR affinity and partial agonism, 4
and 5 displayed high antinociceptive activity in mice when deliv-
ered by icv but also ip injection. As compared with analog 1,
compounds 4 and 5 showed slightly higher antinociception after
icv administration but slightly lower after systemic (ip) adminis-
tration. The conformational analyses in solution and the MolDock
computations suggested that the different ligand-receptor recog-
nition of the pairs 2/3 and 4/5 can be correlated to the different
position and 3D display of the bulky naphthyl groups. On the other
hand, the bioactive conformations adopted within the receptor by
peptides 1 and 4/5 showed similar binding poses which probably
determined their alike pharmacological properties.4. Experimental section
4.1. Materials and methods
All reagents, unless otherwise stated, were purchased from
Sigma Aldrich (Poznan, Poland). Protected amino acids were pur-
chased from Bachem AG (Bubendorf, Switzerland). Opioid radio-
ligands, [3H]DAMGO, [3H][Ile5,6]deltorphin-2 and [3H]nor-BNI were
obtained from Biological Research Centre of Hungarian Academy of
Sciences (Szeged, Hungary). Analytical and semi-preparative RP-
HPLCwas performed usingWaters Breeze instrument (Milford, MA,
USA) with dual absorbance detector (Waters 2487) on Vydac C18
column (5 mm, 4.6  250 mm) and Vydac C18 column (10 mm,
22  250 mm), respectively. Mass spectra of peptides (Supporting
Information) were recorded on FT-ICR (Fourier transform ion
cyclotron resonance) Apex-Qe Ultra 7T instrument (Bruker Dal-
tonics, Bremen, Germany). 1H NMR spectra of peptides were
recorded at 400 MHz in 8:2 DMSO-d6/H2O at room temperature.4.2. Solid-phase peptide synthesis
All peptides were synthesized as previously described by Per-
likowska et al. [18], using techniques for Fmoc-protected amino
acids on MBHA Rink-Amide peptide resin (100e200 mesh,
0.8 mmol/g). Nε-amino group of D-Lys was protected by Mtt, b-
carboxy group of Asp by O-2 PhiPr and hydroxy group of Dmt by t-
butyl (t-Bu). Completion of coupling reactions was monitored by
the chloranil test [47]. Crude peptides were purified by semi-
preparative RP-HPLC using Waters Breeze instrument (Milford,
MA, USA). The correctness of the syntheses was confirmed by HR-
MS.4.3. Opioid receptor binding assays
Opioid receptor binding assays were performed according to the
method described in detail elsewhere [16], using brain homoge-
nates of adult male Wistar rats (for MOR and DOR) or adult male
Dunkin Hartley guinea pigs (for KOR). Binding affinities of peptides
for MOR, DOR and KOR were measured against tritiated radio-
ligands, [3H]DAMGO, [3H][Ile5,6]deltorphin-2 and [3H]nor-BNI,
respectively. The data were analyzed by a nonlinear least square
regression analysis computer program Graph Pad PRISM 6.0
(GraphPad Software Inc., San Diego, USA).
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Enzymatic degradation studies of the new analogs were per-
formed using Wistar rat brain homogenate, following the method
reported in detail previously [16]. Briefly, the analogs were incu-
bated with brain homogenate over 0, 7.5, 15, 22.5, 30 and 90 min at
37 C. The reaction was monitored by RP-HPLC and the amount of
the remaining peptide (area %) was assessed.
4.5. Calcium mobilization assay
CHO cells stably co-expressing human recombinant KOR orMOR
and the C-terminally modified Gaqi5 [48], and CHO cells co-
expressing the human recombinant DOR and the GaqG66Di5
chimeric protein [49], were generated and used in mobilization
assay as previously described [19,28].
Agonist potencies were given as pEC50 representing a negative
logarithm of the molar concentration of an agonist that produces
50% of the maximal possible effect. Concentration response curves
were fitted with the four parameter logistic nonlinear regression
model:
Effect ¼ baselineþ Emax  baseline
1þ 10ðlogEC50XÞ$n
where X is the agonist concentration and n is the Hill coefficient.
Ligand efficacy was expressed as intrinsic activity (a) calculated as
the Emax of the ligand to Emax of the standard agonist ratio. Curve
fittings were performed using GraphPad PRISM 6.0 (GraphPad
Software Inc., San Diego, USA).
4.6. Assessment of antinociception
The procedures used in this study were in accordance with the
European Communities Council Directive (86/609/EEC), and
approved by the Local Ethical Committee for Animal Research at the
Medical University of Lodz with the following number: 29/ŁB 662/
2013.
Male albino mice (BalbC, Animal House, Faculty of Pharmacy,
Lodz, Poland), weighing 20e26 g, were used throughout the study.
The animals were housed under controlled environmental condi-
tions (temperature: 22 ± 1 C, 7 am to 7 pm lightedark cycle) with
free access to standard semi-synthetic laboratory diet and tap
water ad libitum. Mice were tested only once and sacrificed
immediately thereafter by decapitation.
The antinociceptive effects of peptides were assessed in the hot-
plate test, according to the method of Eddy and Leimbach [50] and
adapted in our laboratory by Fichna et al. [17]. The icv injections (10
mL/animal) of peptides or a vehicle were performed in the left brain
ventricle of manually immobilized mice with a Hamilton micro-
syringe (50 mL) connected to a needle (diameter 0.5 mm) while ip
injections (100 mL/animal) were performed into the peritoneum.
The latencies to jumping were measured.
A transparent plastic cylinder (14 cm diameter, 20 cm height)
was used to confine a mouse on the heated (55 ± 0.5 C) surface of
the plate. The animals were placed on the hot-plate 10 min after icv
injection or 15 min after ip injection. A cut-off time of 240 s was
used to avoid tissue injury.
The percentage of the maximal possible effect (%MPE) was
calculated as: %MPE ¼ (t1t0)/(t2t0)  100, where t0 e control
latency, t1-test latency and t2 e cut-off time (240 s). The median
antinociceptive dose (ED50) was calculated as described earlier [16].
The data were analyzed by a nonlinear least square regression
analysis computer program Graph Pad PRISM 6.0 (GraphPad Soft-
ware Inc., San Diego, USA).4.7. NMR analysis
1H NMR spectra were recorded with a Varian Gemini apparatus
at 400 MHz in 5 mm tubes, using 0.01 M peptide at room tem-
perature (Supporting Information). Solvent suppression was per-
formed by the solvent presaturation procedure implemented in
Varian (PRESAT). Chemical shifts were reported as d values relative
to residual DMSO (dH ¼ 2.50 ppm) as internal standard. The un-
ambiguous assignment of 1H NMR resonances was based on
2D gCOSY experiments. VT-1H NMR experiments were performed
over the range of 298e348 K; temperature calibration was done
with the ethylene glycol OHeCH chemical-shift separationmethod.
Dmt-c[D-Lys-D-1-Nal-Phe-Asp]NH2 (2). 1H NMR (400 MHz, 8:2
DMSO-d6/H2O) d: 0.41 (m, 1H, LysHg), 0.66 (m, 1H, LysHg), 1.02 (m,
1H, LysHd), 1.10e1.20 (m, 2H, LysHd þ LysHb), 1.42 (m, 1H, LysHb),
2.13 (s, 6H, DmtMe), 2.32 (dd, J ¼ 3.0, 13.0 Hz, 1H, AspHb), 2.55
(dd,J ¼ 8.2, 13.0 Hz, 1H, AspHb), 2.68e2.75 (m, 2H,
DmtHbþNalHb), 2.76e2.82 (m, 2H, PheHbþ LysHε), 2.83e2.98 (m,
4H, DmtHb þ NalHb þ PheHb þ LysHε), 3.97 (m, 1H, DmtHa), 4.27
(m,1H, LysHa), 4.40 (ddd, J¼ 3.0, 8.0, 8.2 Hz, 1H, AspHa), 4.62e4.72
(m, 2H, PheHa þ NalHa), 6.34 (s, 2H, DmtArH3,5), 7.08e7.20 (m, 5H,
PheArH þ CONH2), 7.22e7.26 (m, 2H, PheArH), 7.34 (m, 1H,
NalArH3), 7.39 (t, J ¼ 6.0 Hz, 1H, LysNHε), 7.51 (t, J ¼ 7.2 Hz, 1H,
NalArH6), 7.57 (t, J¼ 7.2 Hz, 1H, NalArH7), 7.75 (brd, 1H, NalH4), 7.89
(d, J ¼ 8.4 Hz, 1H, NalArH5), 7.90 (d, J ¼ 9.2 Hz, 1H, LysNH), 8.02 (d,
J ¼ 8.0 Hz, 1H, AspNH), 8.12e8.22 (m, 3H, DmtNH þ NalArH8), 8.28
(d, J ¼ 8.8 Hz, 1H, NalNH), 8.66 (d, J ¼ 8.8 Hz, PheNH), 9.01 (s, 1H,
DmtOH).
Dmt-c[D-Lys-D-2-Nal-Phe-Asp]NH2 (3). 1H NMR (400 MHz, 8:2
DMSO-d6/H2O) d: 0.40 (m, 1H, LysHg), 0.65 (m, 1H, LysHg), 1.00 (m,
1H, LysHd), 1.12e1.20 (m, 2H, LysHb þ LysHd), 1.42 (m, 1H, LysHb),
2.13 (s, 6H, DmtMe), 2.32 (dd, J ¼ 3.6, 15.2 Hz, 1H, AspHb),
2.52e2.60 (m, 2H, NalHb þ AspHb), 2.63 (dd, J ¼ 4.0, 14.0 Hz, 1H,
NalHb), 2.69e2.80 (m, 2H, PheHb þ DmtHb), 2.85 (m, 1H, LysHε),
2.89e3.00 (m, 3H, DmtHb þ PheHb þ LysHε), 3.96 (m, 1H, DmtHa),
4.32 (m, 1H, LysHa), 4.38 (ddd, J ¼ 3.6, 4.8, 8.0 Hz, 1H, AspHa), 4.60
(ddd, J ¼ 4.0, 6.0, 9.6 Hz, 1H, PheHa), 4.65 (ddd, J ¼ 4.0, 7.2, 8.8 Hz,
1H,NalHa), 6.34 (s, 2H, DmtArH3,5), 7.06 (s, 1H, CONH2), 7.12e7.19
(m, 4H, CONH2 þ PheArH), 7.20e7.24 (m, 2H, PheArH), 7.27 (d,
J ¼ 8.0 Hz, NalArH3), 7.32 (t, J ¼ 6.0 Hz, 1H, LysNHε), 7.42e7.49 (m,
2H, NalArH6,7), 7.60 (s, 1H, NalArH1), 7.76 (d, J ¼ 8.0 Hz, 1H,
NalArH4), 7.83 (d, J ¼ 8.0 Hz, 1H, NalArH5), 7.90 (d, J ¼ 7.6 Hz, 1H,
LysNH), 8.01 (d, J ¼ 8.0 Hz, 1H, AspNH), 8.11 (br.s, 2H, DmtNH), 8.20
(d, J¼ 8.8 Hz,1H, NalNH), 8.59 (d, J¼ 8.4 Hz,1H, PheNH), 9.00 (s,1H,
DmtOH).
Dmt-c[D-Lys-Phe-D-1-Nal-Asp]NH2 (4). 1H NMR (400 MHz, 8:2
DMSO-d6/H2O) d: 0.64 (m, 1H, LysHg), 0.84 (m, 1H, LysHg), 1.04 (m,
1H, LysHb), 1.11 (m, 1H, LysHd), 1.23 (m, 1H, LysHd), 1.32 (m, 1H,
LysHb), 2.13 (s, 6H, DmtMe), 2.31 (dd, J ¼ 6.0, 13.2 Hz, 1H, PheHb),
2.34e2.44 (m, 2H, PheHb þ AspHb), 2.58 (dd, J ¼ 10.2, 15.8 Hz, 1H,
AspHb), 2.80 (m, 1H, LysHε), 2.87 (m, 1H, DmtHb), 2.92e3.00 (m,
2H, NalHb þ DmtHb), 3.10 (m, 1H, LysHε), 3.66 (dd, J ¼ 3.2, 14.4 Hz,
1H, NalHb), 3.70 (m, 1H, DmtHa), 4.05 (ddd, J ¼ 6.4, 7.6, 9.2 Hz, 1H,
LysHa), 4.40e4.48 (m, 2H, PheHa þ AspHa), 4.54 (ddd, J ¼ 4.0, 9.2,
13.2 Hz, 1H, NalHa), 6.40 (s, 2H, DmtArH3,5), 6.87e6.92 (m, 2H,
PheArH), 7.09e7.12 (m, 4H, PheArHþ CONH2), 7.18 (d, J¼ 7.6 Hz,1H,
PheNH), 7.23 (s, 1H, CONH2), 7.32e7.40 (m, 2H, NalArH2,3), 7.53 (t,
J ¼ 7.2 Hz, 1H, NalArH6), 7.56e7.62 (m, 2H, LysNHε þ NalArH7), 7.64
(d, J ¼ 7.6 Hz, 1H, AspNH), 7.51 (d, J ¼ 9.2 Hz, 1H, LysNH), 7.77 (d,
J ¼ 8.0 Hz, 1H, NalArH4), 7.92 (d, J ¼ 8.0 Hz, 1H, NalArH5), 8.10 (d,
J ¼ 8.0 Hz, 1H, NalArH8), 8.34 (m, 2H, DmtNH), 8.61 (d, J ¼ 9.2 Hz,
1H, NalNH), 9.10 (s, 1H, DmtOH).
Dmt-c[D-Lys-Phe-D-2-Nal-Asp]NH2 (5). 1H NMR (400 MHz, 8:2
DMSO-d6/H2O) d: 0.64 (m, 1H, LysHg), 0.85 (m, 1H, LysHg),
1.02e1.10 (m, 2H, LysHb þ LysHd), 1.23 (m, 1H, LysHd), 1.33 (m, 1H,
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2.40e2.45 (m, 2H, PheHb), 2.52 (dd, J ¼ 9.2, 15.6 Hz, 1H, AspHb),
2.79 (m, 1H, LysHε), 2.86 (m, 1H, NalHb), 2.88 (m, 1H, DmtHb), 2.97
(dd, J ¼ 12.0, 13.2 Hz, 1H, DmtHb), 3.09 (dd, J ¼ 4.6, 13.6 Hz, 1H,
NalHb), 3.17 (m, 1H, LysHε), 3.72 (m, 1H, DmtHa), 4.08 (m, 1H,
LysHa), 4.34e4.43 (m, 2H, AspHa þ PheHa), 4.56 (ddd, J ¼ 4.6, 8.8,
9.2 Hz, 1H, NalHa), 6.41 (s, 2H, DmtArH3,5), 6.86 (d, J ¼ 5.6 Hz, 2H,
PheArH2,6), 7.04e7.14 (m, 5H, PheArH3e5 þ CONH2), 7.18 (d,
J ¼ 8.4 Hz, 1H, NalArH3), 7.25 (d, J ¼ 8.0 Hz, 1H, PheNH), 7.40e7.48
(m, 2H, NalArH6,7), 7.52e7.56 (m, 2H, AspNH þ NalArH1), 7.57 (br.t,
1H, LysNHε), 7.75 (d, J ¼ 8.8 Hz, 2H, NalArH8 þ LysNH), 7.79 (d,
J ¼ 8.0 Hz, 1H, NalArH4), 7.83 (d, J ¼ 8.0 Hz, 1H, NalArH5), 8.31 (br.s,
2H, DmtNH), 8.43 (d, J ¼ 9.2 Hz, 1H, NalNH), 9.13 (s, 1H, DmtOH).
4.8. 2D ROESY analyses
The experiments were conducted in DMSO-d6/H2O (8:2) in the
phase-sensitive mode at room temperature, spin-locking field
(gb2) was 2000 Hz, and mixing time was set to 250 ms; spectra
were processed in the hypercomplex approach; peaks were cali-
brated on DMSO. Cross-peak intensities were classified as very
strong, strong, medium, and weak, and were associated with dis-
tances of 2.3, 2.7, 3.3, and 5.0 Å, respectively (Supporting Infor-
mation). The intensities of the cross peaks arising from protons
separated by known distances (e.g., geminal) were found to match
with these associations. Geminal and other clear correlations were
discarded as constraints. For the absence of Ha(i, iþ 1) ROESY cross
peaks, all of the u bonds were set at 1808 (force constant:
16 k cal mol1 Å2).
4.9. Restrained molecular dynamics
Only ROESY-derived constraints were included in the MD sim-
ulations [51]. The experiments were conducted at 300 K and 1 atm
by using the AMBER force field in a 30  30  30 Å box of standard
TIP3P models of equilibrated water [52]. Periodic boundary con-
ditions were applied, a dielectric constant of 1was used, and the cut
off distance for the non-bonded interactions was 12 Å. All water
molecules with atoms that come closer than 2.3 Å to a solute atom
were eliminated. A 100 ps simulation at 1200 K was used for
generating 50 random structures that were subsequently subjected
to a 50 ps restrained MD with a 50% scaled force field at the same
temperature, followed by 50 ps with full restraints (distance force
constant of 7 kcal mol1 Å2), after which the systemwas cooled in
20 pse50 K. H-bond interactions were not included, nor were
torsion angle restraints. The resulting structures were minimized
with 3000 cycles of steepest descent and 3000 cycles of conjugated
gradient (convergence of 0.01 kcalÅ1 mol1). The backbones of the
structures were clustered by the rmsd analysis.
4.10. Molecular docking
The previously reported procedure [41,45], using a homology
models of hMOR subsequently validated with the crystallographic
structure disclosed in 2012 [2] was utilized. The initial structures of
the ligandswere the ROESY-derived structures of the cyclopeptides.
MolDock experiments were performed with Autodock 4.0 [43],
which uses an empirical scoring function based on the free energy
of binding. The ligands and the MOR were further processed using
the Autodock Tool Kit. Gasteiger-Marsili charges were assigned and
solvation parameters were added to the final docked structure
using Addsol utility. Structures with less than 1.0 A rmsd were
clustered together and representative model of each cluster was
selected based on the most favourable free energy of binding. Vi-
sual inspection was carried out to select the final structure. Thecombined QM/MM approach, as implemented in NWChem [53]
was used. The QM/MM module in NWChem was built as a top
level interface between the classical MD module and various QM
modules, managing initialization, data transfer, and various high
level operation. For the QM/MM calculations, the ligand-receptor
systems resulting from the MolDock study were first partitioned
into a QM subsystem and an MM subsystem. The reaction system
used a smaller QM subsystem consisting of the ligand and residues
within 4.5 Å, whereas the MM subsystem was treated using a
modified AMBER force field. The boundary problem between the
QM and MM subsystems was treated using the pseudo-bond
approach. With this QM/MM system, an iterative optimization
procedurewas applied to the QM/MM system, using 3-21G⁄QM/MM
calculations, leading to an optimized structure for the reactants.
The convergence criterion used was set to obtain an energy
gradient of <104, using the twin-range cut off method for non-
bonded interactions, with a long-range cut off of 14 Å and a
short-range cut off of 8 Å.
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